for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pulmatrix Inc

PULM.OQ

Latest Trade

0.88USD

Change

0.03(+4.09%)

Volume

32,686

Today's Range

0.84

 - 

0.88

52 Week Range

0.72

 - 

4.60

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.84
Open
0.85
Volume
32,686
3M AVG Volume
4.04
Today's High
0.88
Today's Low
0.84
52 Week High
4.60
52 Week Low
0.72
Shares Out (MIL)
19.62
Market Cap (MIL)
16.80
Forward P/E
-0.86
Dividend (Yield %)
--

Next Event

Q3 2019 Pulmatrix Inc Earnings Release

Latest Developments

More

Pulmatrix Reports Q2 2019 Results

Pulmatrix Says Received Non-Compliance Letter From Nasdaq

Sabby Management Reports 5.19% Passive Stake In Pulmatrix Inc

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pulmatrix Inc

Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease.

Industry

Biotechnology & Drugs

Contact Info

99 Hayden Ave Ste 390

+1.781.3572333

http://www.pulmatrix.com/

Executive Leadership

Mark T. Iwicki

Independent Chairman of the Board

Teofilo Raad

Chief Executive Officer, Director

William E. Duke

Chief Financial Officer

David L. Hava

Chief Scientific Officer

Jean Sung

Vice President - Pharmaceutical Development

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-4.980

2019(E)

-1.000
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.49
Price To Book (MRQ)
0.93
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-107.83
Return on Equity (TTM)
-76.89

Latest News

BRIEF-Pulmatrix Reports 2017 Financial Results; Provides 2018 Outlook On Pulmonary Disease Pipeline

* PULMATRIX REPORTS 2017 FINANCIAL RESULTS; PROVIDES 2018 OUTLOOK ON PULMONARY DISEASE PIPELINE

BRIEF-Pulmatrix Announces First Subject Dosed In Phase 1 Clinical Trial Of Pulmazole

* PULMATRIX ANNOUNCES FIRST SUBJECT DOSED IN PHASE 1 CLINICAL TRIAL OF PULMAZOLE - AN INHALED DRY-POWDER ISPERSE™ FORMULATION OF ITRACONAZOLE

BRIEF-Pulmatrix posts Q3 net loss of $0.22 per share

* Pulmatrix provides Q3 2017 highlights and Q3 2017 updated financials

BRIEF-Vectura signs VR410 agreement with Pulmatrix

* PROGRESSING DEVELOPMENT OF BRANDED GENERIC TIOTROPIUM BROMIDE PROGRAMME (VR410) FOR US MARKET, ACCELERATED THROUGH LICENCE DEAL WITH PULMATRIX

BRIEF-Pulmatrix says generated no revenue in Q2 of 2017

* Pulmatrix provides 2017 company year-to-date highlights and q2 2017 updated financials

BRIEF-Pulmatrix to pay Respivert up-front, non-refundable license fee of $1 mln

* Pulmatrix - will pay Respivert up-front, non-refundable license fee of $1 million in partial consideration for rights granted by respivert to company - sec filing

BRIEF-Pulmatrix licenses novel drug candidates from Respivert

* Pulmatrix licenses novel drug candidates from Respivert Ltd., a wholly owned subsidiary of Janssen Biotech, Inc.

BRIEF-Pulmatrix says received key patent in U.S. For PUR0200

* Received key patent in U.S. for its lead drug candidate, PUR0200, which is intended to treat chronic obstructive pulmonary diseases

BRIEF-Pulmatrix reports qtrly loss per share $0.21

* Pulmatrix Inc - pulmatrix generated no revenues in Q1 of 2017, compared to $0.4 million for Q1 of 2016 Source text for Eikon: Further company coverage:

BRIEF-Pulmatrix receives European patent for inhaled drug delivery technology

* Pulmatrix receives European patent for its inhaled drug delivery technology Source text for Eikon: Further company coverage:

BRIEF-Pulmatrix enters into an at-the-market sales agreement

* Pulmatrix- issuance, sale of up to $11 million of co's shares of common stock, par value $0.0001 per share from time to time in at-the-market public offering Source text for Eikon: Further company coverage:

BRIEF-Pulmatrix reports 2016 financial results provides

* Pulmatrix reports 2016 financial results; provides 2017 outlook on pulmonary disease pipeline

BRIEF-PULMATRIX ANNOUNCES OVER $3 MLN REGISTERED DIRECT OFFERING

* PULMATRIX ANNOUNCES OVER $3.0 MILLION REGISTERED DIRECT OFFERING

BRIEF-Pulmatrix announces $5 million registered direct offering

* Pulmatrix inc- company agreed to sell an aggregate of approximately 2 million shares of common stock, at a price of $2.50 per share

BRIEF-PULMATRIX DRUG CANDIDATE RECEIVES QIDP DESIGNATION FROM FDA

* PULMATRIX DRUG CANDIDATE RECEIVES "QUALIFIED INFECTIOUS DISEASE PRODUCT" (QIDP) DESIGNATION FROM THE FDA

BRIEF-Pulmatrix presents data on inhaled drug delivery platform

* Pulmatrix -New study shows Co's inhaled drug delivery platform successfully delivers higher doses of antifungal drug to lungs compared to oral delivery

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up